The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years
Abstract
OBJECTIVE: To characterize the safety profile of tenofovir disoproxil fumarate (DF) for the treatment of HIV infection in adults over the first 4 years of use. METHODS: A tenofovir DF expanded access program (EAP) was initiated in 2001; safety data were examined from this program and from the manufacturer's database, which contained reports of all postmarketing adverse drug reactions received up to 30 April 2005. Specific analyses were performed to characterize the renal safety of tenofovir DF. RESULTS: The EAP enrolled 10 343 patients; serious adverse events (SAEs) were reported in 631 (6%). A renal SAE of any type was observed in 0.5% of patients, and graded elevations in serum creatinine occurred in 2.2% of the patients evaluated. In a multivariate analysis, baseline risk factors for the development of increased serum creatinine on-study were elevated serum creatinine, concomitant nephrotoxic medications, low body weight, advanced age, and lower CD4 cell count. For postmarketing safety data (455 392 person-years of exposure to tenofovir DF) the most commonly reported serious adverse drug reactions were renal events, with a distribution by type similar to that observed in the EAP. Bone abnormalities were infrequently reported in either the EAP or the postmarketing safety databases. No new unexpected toxicities were identified in postmarketing safety surveillance. CONCLUSIONS: The data demonstrate a favorable safety profile for tenofovir DF in the treatment of adults with HIV infection. Risk factors for development of nephrotoxicity can be identified and may be useful in managing those patients at greatest risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prediction of Creatinine Clearance from Serum Creatinine
Cockcroft, D. W., & Gault, H. (1976) · Nephron · doi:10.1159/000180580 · Cited by 15,309
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Gallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341 · cited 3×
“serum creatinine, have been reported for tenofovir DFtreated patients in some [8,9,17] but not all [3,16] studies.”
BackgroundResultTenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV
Gallant, J. E., DeJesus, E., Arribas, J. R., Pozniak, A. L., Gazzard, B., Campo, R. E., Lu, B., McColl, D., Chuck, S., Enejosa, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa051871 · Cited by 880
Self-citationReport of the committee on the genetic constitution of autosomes other than chromosomes 1, 2, and 6
Ruddle, F. H., & Meera Khan, P. (1976) · Cytogenetic and Genome Research · doi:10.1159/000130554 · Cited by 845
Gupta, S. K., Eustace, J. A., Winston, J. A., Boydstun, I. I., Ahuja, T. S., Rodriguez, R. A., Tashima, K. T., Roland, M., Franceschini, N., Palella, F. J., et al. (2005) · Clinical Infectious Diseases · doi:10.1086/430257 · Cited by 581
Karras, A., Lafaurie, M., Furco, A., Bourgarit, A., Droz, D., Sereni, D., Legendre, C., Martinez, F., & Molina, J. (2003) · Clinical Infectious Diseases · doi:10.1086/368314 · Cited by 361
Fanconi syndrome and renal failure induced by tenofovir: A first case report
Verhelst, D., Monge, M., Meynard, J.-L., Fouqueray, B., Mougenot, B., Girard, P.-M., Ronco, P., & Rossert, J. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.36924 · Cited by 349
Gallant, J. E., Parish, M. A., Keruly, J. C., & Moore, R. D. (2005) · Clinical Infectious Diseases · doi:10.1086/428840 · Cited by 302
Schooley, R. T., Ruane, P., Myers, R. A., Beall, G., Lampiris, H., Berger, D., Chen, S.-S., Miller, M. D., Isaacson, E., & Cheng, A. K. (2002) · AIDS · doi:10.1097/00002030-200206140-00008 · Cited by 270
Self-citationRenal Tubular Dysfunction Associated With Tenofovir Therapy: Report of 7 Cases
Peyri??re, H., Reynes, J., Rouanet, I., Daniel, N., de Boever, C. M., Mauboussin, J.-M., Leray, H., Moachon, L., Vincent, D., & Salmon-C??ron, D. (2004) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200403010-00007 · Cited by 262
Predictors of proteinuria and renal failure among women with HIV infection
Szczech, L. A., Gange, S. J., van der Horst, C., Bartlett, J. A., Young, M., Cohen, M. H., Anastos, K., Klassen, P. S., & Svetkey, L. P. (2002) · Kidney International · doi:10.1046/j.1523-1755.2002.00094.x · Cited by 241
Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection: A Randomized Trial
Squires, K., Pozniak, A. L., Pierone, G., Steinhart, C. R., Berger, D., Bellos, N. C., Becker, S. L., Wulfsohn, M., Miller, M. D., Toole, J. J., et al. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-5_part_1-200309020-00006 · Cited by 198
Wyatt, C. M., Arons, R. R., Klotman, P. E., & Klotman, M. E. (2006) · AIDS · doi:10.1097/01.aids.0000210610.52836.07 · Cited by 184
Self-citationIzzedine, H., Hulot, J. S., Vittecoq, D., Gallant, J. E., Staszewski, S., Launay-Vacher, V., Cheng, A., Deray, G., & for the Study 903 Team (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh658 · Cited by 182
Renal safety of tenofovir in HIV treatment-experienced patients
Izzedine, H., Isnard-Bagnis, C., Hulot, J. S., Vittecoq, D., Cheng, A., Jais, C. K., Launay-Vacher, V., & Deray, G. (2004) · AIDS · doi:10.1097/00002030-200404300-00019 · Cited by 173
Development of Proteinuria or Elevated Serum Creatinine and Mortality in HIV-Infected Women
Gardner, L. I., Holmberg, S. D., Williamson, J. M., Szczech, L. A., Carpenter, C. C. J., Rompalo, A. M., Schuman, P., & Klein, R. S. (2003) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200302010-00013 · Cited by 172
Coca, S. G., & Perazella, M. A. (2002) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200212000-00011 · Cited by 154
Rollot, F., Nazal, E.-M., Chauvelot‐Moachon, L., Kelaïdi, C., Daniel, N., Saba, M., Abad, S., & Blanche, P. (2003) · Clinical Infectious Diseases · doi:10.1086/379829 · Cited by 131
Renal lesions in HIV-1-positive patient treated with tenofovir
Créput, C., Gonzalez-Canali, G., Hill, G. S., Piketty, C., Kazatchkine, M. D., & Nochy, D. (2003) · AIDS · doi:10.1097/00002030-200304110-00026 · Cited by 116
Antiretroviral therapy with tenofovir is associated with mild renal dysfunction
Mauss, S., Berger, F., & Schmutz, G. (2004) · AIDS · doi:10.1097/00002030-200501030-00012 · Cited by 113
Neurological and neuropsychiatric syndromes associated with liver disease
Weißenborn, K., Bokemeyer, M., Krause, J., Ennen, J. C., & Ahl, B. (2005) · AIDS · doi:10.1097/01.aids.0000192076.03443.6d · Cited by 106
Incidence of and risk factors for tenofovir‐induced nephrotoxicity: a retrospective cohort study
Antoniou, T., Raboud, J., Chirhin, S., Yoong, D., Govan, V., Gough, K. A., Rachlis, A., & Loutfy, M. (2005) · HIV Medicine · doi:10.1111/j.1468-1293.2005.00308.x · Cited by 105
Winston, A., Amin, J., Mallon, P. W. G., Marriott, D., Carr, A. D., Cooper, D., & Emery, S. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00349.x · Cited by 94
Self-citationLong-Term Renal Effects of Low-Dose Cyclosporine in Uveitis-Treated Patients: Follow-Up Study
Bagnis, C. I., du Montcel, S. T., Beaufils, H. A. A. G. A., Jouanneau, C., Jaudon, M. C., Maksud, P., Mallet, A., LeHoang, P., & Deray, G. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000034945.61533.26 · Cited by 79
Reisler, R. B., Murphy, R. L., Redfield, R., & Parker, R. A. (2005) · PubMed · Cited by 55
Electrolyte and acid-base disorders associated with AIDS
Perazella, M. A., & Brown, E. (1994) · Journal of General Internal Medicine · doi:10.1007/bf02600132 · Cited by 52
Cited by
Thompson, M. A., Aberg, J. A., Hoy, J. F., Telenti, A., Benson, C., Cahn, P., Eron, J. J., Günthard, H. F., Hammer, S. M., Reiss, P., et al. (2012) · JAMA · doi:10.1001/jama.2012.7961 · Cited by 2,469
Cooper, R. D., Wiebe, N., Smith, N., Keiser, P., Naicker, S., & Tonelli, M. (2010) · Clinical Infectious Diseases · doi:10.1086/655681 · Cited by 565
Effros, R. B., Fletcher, C. V., Gebo, K., Halter, J. B., Hazzard, W. R., Horne, F. M., Huebner, R. E., Janoff, E. N., Justice, A. C., Kuritzkes, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590150 · Cited by 539
Association of tenofovir exposure with kidney disease risk in HIV infection
Scherzer, R., Estrella, M., Li, Y., Choi, A. I., Deeks, S. G., Grunfeld, C., & Shlipak, M. G. (2012) · AIDS · doi:10.1097/qad.0b013e328351f68f · Cited by 424
Ray, A. S., Fordyce, M. W., & Hitchcock, M. J. M. (2016) · Antiviral Research · doi:10.1016/j.antiviral.2015.11.009 · Cited by 392
Metadata
- Authors
- Nelson, M. R., Katlama, C., Montaner, J. S., Cooper, D. A., Gazzard, B., Clotet, B., Lazzarin, A., Schewe, K., Lange, J., Wyatt, C., Curtis, S., Chen, S.-S., Smith, S., Bischofberger, N., & Rooney, J. F.
- Venue
- AIDS
- Published
- 2007-06
- Volume
- 21
- Issue
- 10
- Pages
- 1273-1281
- ISSN
- 0269-9370 (ISSN-L)
- OpenAlex
- W2005270107
- Cited by
- 352
- References
- 27
- FWCI
- 16.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.